Combating opportunistic infections: Coccidioidomycosis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Coccidioidomycosis is a growing problem in the southwestern US. Although most cases of symptomatic coccidioidomycosis occur in healthy individuals, individuals with depressed cellular immunity are at particular risk. These include individuals with HIV infection, those who have undergone allogeneic transplantation and others on immunosuppressive medications. Most instances of primary pulmonary coccidioidomycosis do not require antifungal therapy. However, almost all cases of disseminated coccidioidomycosis will require such therapy. The triazole antifungals, fluconazole and itraconazole, are effective therapies for coccidioidomycosis. Amphotericin B is now reserved for severe or recalcitrant cases. Coccidioidal meningitis requires life-long therapy with triazole antifungals. Intrathecal amphotericin B is required for those cases that fail. Prevention of coccidioidomycosis by environmental control is difficult. In the future, immunisation or immune modulation may offer protection.

Original languageEnglish (US)
Pages (from-to)255-261
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume5
Issue number2
DOIs
StatePublished - Feb 2004

Fingerprint

Coccidioidomycosis
Opportunistic Infections
Triazoles
Amphotericin B
Itraconazole
Fluconazole
Homologous Transplantation
Therapeutics
Immunosuppressive Agents
Meningitis
Cellular Immunity
HIV Infections
Immunization
Lung

Keywords

  • Amphotericin B
  • Coccidioides
  • Coccidioidomycosis
  • Triazoles

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Combating opportunistic infections : Coccidioidomycosis. / Ampel, Neil M.

In: Expert Opinion on Pharmacotherapy, Vol. 5, No. 2, 02.2004, p. 255-261.

Research output: Contribution to journalArticle

@article{0a1f01e6beb748c1b3f565b4411e919e,
title = "Combating opportunistic infections: Coccidioidomycosis",
abstract = "Coccidioidomycosis is a growing problem in the southwestern US. Although most cases of symptomatic coccidioidomycosis occur in healthy individuals, individuals with depressed cellular immunity are at particular risk. These include individuals with HIV infection, those who have undergone allogeneic transplantation and others on immunosuppressive medications. Most instances of primary pulmonary coccidioidomycosis do not require antifungal therapy. However, almost all cases of disseminated coccidioidomycosis will require such therapy. The triazole antifungals, fluconazole and itraconazole, are effective therapies for coccidioidomycosis. Amphotericin B is now reserved for severe or recalcitrant cases. Coccidioidal meningitis requires life-long therapy with triazole antifungals. Intrathecal amphotericin B is required for those cases that fail. Prevention of coccidioidomycosis by environmental control is difficult. In the future, immunisation or immune modulation may offer protection.",
keywords = "Amphotericin B, Coccidioides, Coccidioidomycosis, Triazoles",
author = "Ampel, {Neil M.}",
year = "2004",
month = "2",
doi = "10.1517/14656566.5.2.255",
language = "English (US)",
volume = "5",
pages = "255--261",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Combating opportunistic infections

T2 - Coccidioidomycosis

AU - Ampel, Neil M.

PY - 2004/2

Y1 - 2004/2

N2 - Coccidioidomycosis is a growing problem in the southwestern US. Although most cases of symptomatic coccidioidomycosis occur in healthy individuals, individuals with depressed cellular immunity are at particular risk. These include individuals with HIV infection, those who have undergone allogeneic transplantation and others on immunosuppressive medications. Most instances of primary pulmonary coccidioidomycosis do not require antifungal therapy. However, almost all cases of disseminated coccidioidomycosis will require such therapy. The triazole antifungals, fluconazole and itraconazole, are effective therapies for coccidioidomycosis. Amphotericin B is now reserved for severe or recalcitrant cases. Coccidioidal meningitis requires life-long therapy with triazole antifungals. Intrathecal amphotericin B is required for those cases that fail. Prevention of coccidioidomycosis by environmental control is difficult. In the future, immunisation or immune modulation may offer protection.

AB - Coccidioidomycosis is a growing problem in the southwestern US. Although most cases of symptomatic coccidioidomycosis occur in healthy individuals, individuals with depressed cellular immunity are at particular risk. These include individuals with HIV infection, those who have undergone allogeneic transplantation and others on immunosuppressive medications. Most instances of primary pulmonary coccidioidomycosis do not require antifungal therapy. However, almost all cases of disseminated coccidioidomycosis will require such therapy. The triazole antifungals, fluconazole and itraconazole, are effective therapies for coccidioidomycosis. Amphotericin B is now reserved for severe or recalcitrant cases. Coccidioidal meningitis requires life-long therapy with triazole antifungals. Intrathecal amphotericin B is required for those cases that fail. Prevention of coccidioidomycosis by environmental control is difficult. In the future, immunisation or immune modulation may offer protection.

KW - Amphotericin B

KW - Coccidioides

KW - Coccidioidomycosis

KW - Triazoles

UR - http://www.scopus.com/inward/record.url?scp=1242274392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242274392&partnerID=8YFLogxK

U2 - 10.1517/14656566.5.2.255

DO - 10.1517/14656566.5.2.255

M3 - Article

C2 - 14996623

AN - SCOPUS:1242274392

VL - 5

SP - 255

EP - 261

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -